Diuretic EffectNCT07348510
Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures
A study testing Aminophylline and Furosemide in people with Diuretic Effect and Aminophylline, run by Cairo University at 1 site in Egypt.
Trial summary
This work aims to investigate the diuretic effect of Aminophylline in comparison to Furosemide in adult patients undergoing cardiac surgical procedures. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Diuretic Effect, Aminophylline, Furosemide
- What is being tested?
- Aminophylline and Furosemide
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 106 participants
- Where
- 1 siteEgypt
- Study dates
- 17 Jan 2026to 26 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age from 18-65 years.
- Both sexes.
- All adult patients presenting for elective cardiac surgical procedures performed on cardiopulmonary bypass (Coronary artery bypass surgery, Cardiac valve repair and/or replacement, Repair of large septal defects, Repair and/or palliation of congenital heart defects, Transplantation, surgery of thoracic aneurysms.).
- Body mass index (BMI) ranged between 20 and 40 kg/m2.
Who cannot join
- Sensitivity or contraindication to Aminophylline or furosemide
- Stage-5 chronic kidney disease (CKD) [Glomerular filtration rate (GFR) of less than 15 mL/min].
- The presence of both factors (GFR less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease.
- Recipients of dialysis before surgery.
- Recipients of solid-organ transplantation before surgery.
- Emergency cardiac surgical procedures (e.g. left main coronary artery bypass graft, stuck valves, etc).
- Patient refusal.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo University
Cairo, 12613
Ahmed M Hassan, MSc, 00201033752020, ahm33hassan@gmail.com
Maged Salah, MD
About this study
Official title: Comparison Between the Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures: A Randomized Controlled Trial
This work aims to investigate the diuretic effect of Aminophylline in comparison to Furosemide in adult patients undergoing cardiac surgical procedures.
Read the detailed description
Acute Kidney injury (AKI) is a serious and common complication after either adult or pediatric cardiac surgery.
The results of a recent meta-analysis suggested that loop diuretics (furosemide) may reduce postoperative creatinine clearance, whereas aldosterone agonists (spironolactone) increase the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI). Diuretics are not recommended for the prevention of AKI, but loop diuretics may be used for the management of volume overload Aminophylline in cardiac surgery can reduce the frequency of AKI and could be used in the prevention of AKI as a safe and efficient modality in high-risk patients.
- Being tested
- Aminophylline, Furosemide
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AminophyllineDrug
Patients will receive Aminophylline.
FurosemideDrug
Patients will receive furosemide.
| Study group | Role | What they receive |
|---|---|---|
| Aminophylline group (control group) | Active comparator | Patients will receive Aminophylline. Receives: Drug: Aminophylline |
| Furosemide group | Experimental | Patients will receive furosemide. Receives: Drug: Furosemide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of urine output
Urine output will be measured at two hours after cardiopulmonary bypass.
Measured: Two hours after cardiopulmonary bypass
Secondary outcomes (6)
Measurement of urine output at completion of cardiopulmonary bypass
Urine output at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB.
Measured: 48 hours after cardiopulmonary bypass
Urea level
Urea level will be measured at 8 hours and 48 hours after cardiopulmonary bypass.
Measured: 48 hours after cardiopulmonary bypass
Creatinine level
Creatinine level will be measured at 8 hours and 48 hours after cardiopulmonary bypass.
Measured: 48 hours after cardiopulmonary bypass
Lactate level
Lactate level will be measured at 8 hours and 48 hours after cardiopulmonary bypass.
Measured: 48 hours after cardiopulmonary bypass
Estimated Glomerular Filtration Rate (eGFR)
Estimated Glomerular Filtration Rate (eGFR) at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB.
Measured: 48 hours after cardiopulmonary bypass
Measurement of fluid balance
Fluid balance at completion of cardiopulmonary bypass (CPB) will be measured at 8 hours and 48 hours after CPB.
Measured: 48 hours after cardiopulmonary bypass
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start17 Jan 2026
- Primary completion26 Jul 2026 (estimated)
- Study completion26 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diuretic EffectStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 106 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Mohamed Hassan, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07348510
- Sponsor's protocol ID
- MD-258-2024
- Status last verified
- Jan 2026
- First submitted
- 7 Jan 2026
- Last updated
- 21 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between the Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07348510
- Acronym / sponsor ID
- MD-258-2024
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 106 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 17 Jan 2026 (actual)
- Primary completion
- 26 Jul 2026 (estimated)
- Study completion
- 26 Jul 2026 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This work aims to investigate the diuretic effect of Aminophylline in comparison to Furosemide in adult patients undergoing cardiac surgical procedures.
Detailed description
Acute Kidney injury (AKI) is a serious and common complication after either adult or pediatric cardiac surgery.
The results of a recent meta-analysis suggested that loop diuretics (furosemide) may reduce postoperative creatinine clearance, whereas aldosterone agonists (spironolactone) increase the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI). Diuretics are not recommended for the prevention of AKI, but loop diuretics may be used for the management of volume overload Aminophylline in cardiac surgery can reduce the frequency of AKI and could be used in the prevention of AKI as a safe and efficient modality in high-risk patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Aminophylline group (control group) | Active comparator | Drug: AminophyllinePatients will receive Aminophylline. |
| Furosemide group | Experimental | Drug: FurosemidePatients will receive furosemide. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age from 18-65 years.
- Both sexes.
- All adult patients presenting for elective cardiac surgical procedures performed on cardiopulmonary bypass (Coronary artery bypass surgery, Cardiac valve repair and/or replacement, Repair of large septal defects, Repair and/or palliation of congenital heart defects, Transplantation, surgery of thoracic aneurysms.).
- Body mass index (BMI) ranged between 20 and 40 kg/m2.
Key exclusion criteria (7 listed)
- Sensitivity or contraindication to Aminophylline or furosemide
- Stage-5 chronic kidney disease (CKD) [Glomerular filtration rate (GFR) of less than 15 mL/min].
- The presence of both factors (GFR less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease.
- Recipients of dialysis before surgery.
- Recipients of solid-organ transplantation before surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AminophyllinePatients will receive Aminophylline. | Drug | Aminophylline group (control group) |
| FurosemidePatients will receive furosemide. | Drug | Furosemide group |
Primary outcome
Measurement of urine output
Time frame: Two hours after cardiopulmonary bypass
Urine output will be measured at two hours after cardiopulmonary bypass.
6 secondary outcomes
Measurement of urine output at completion of cardiopulmonary bypass
Time frame: 48 hours after cardiopulmonary bypass
Urea level
Time frame: 48 hours after cardiopulmonary bypass
Creatinine level
Time frame: 48 hours after cardiopulmonary bypass
Lactate level
Time frame: 48 hours after cardiopulmonary bypass
Estimated Glomerular Filtration Rate (eGFR)
Time frame: 48 hours after cardiopulmonary bypass
Measurement of fluid balance
Time frame: 48 hours after cardiopulmonary bypass
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Diuretic Effect
Recruiting
Evaluation of the Effects of Sauna Therapy on Congestion and Loop Diuretic Use in Patients With Heart Failure With Reduced or Moderately Reduced Ejection Fraction
Heart Failure
RecruitingPhase 3
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
Uncontrolled Hypertension
Recruiting
"Effect of Albumin Combined With Furosemide in Critically Ill Patients With Fluid Overload: Impact on Urine Output and Renal Function"
Urine Output Decreased
Recruiting
Effect of Giving Reduced Fluid in Children After Trauma
Critical Illness, Pediatrics
Not yet recruitingPhase 2/3
POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure
Acute Heart Failure (AHF), Congestive Heart Failure Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aminophylline and Furosemide in people with Diuretic Effect and Aminophylline, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed M Hassan, MSc (00201033752020, ahm33hassan@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of urine output (time frame: Two hours after cardiopulmonary bypass). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.